CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of prostate cancer.
  
  LEARNING OBJECTIVES

  • Apply clinical research findings in the selection and sequencing of available local and systemic treatment modalities for patients with metastatic prostate cancer.
  • Evaluate the published research database supporting the use of cytotoxic and secondary hormonal therapy in the setting of metastatic hormone-sensitive prostate cancer (mHSPC) to design effective treatment plans for patients.
  • Recall the recent FDA approvals of enzalutamide and apalutamide for patients with mHSPC, and effectively integrate these agents into clinical practice.
  • Consider the adverse effects associated with hormonal agents commonly employed in the treatment of prostate cancer, and develop strategies to prevent, mitigate and manage these toxicities.
  • Explore available and emerging research data on the optimal management of metastatic castration-resistant prostate cancer, and apply recent advances to current clinical care.
  • Understand the rationale for genetic testing for BRCA1/2 and other mutations in patients with prostate cancer, and advise those found to harbor these genetic alterations about the FDA approvals and potential benefits of PARP inhibitors.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Andrew J Armstrong, MD, ScM
  Professor of Medicine, Surgery, Pharmacology and Cancer Biology
  Director of Research
  Duke Cancer Institute Center for Prostate and Urologic Cancers
  Divisions of Medical Oncology and Urology
  Duke University
  Durham, North Carolina
  
  Advisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Merck; Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genomic Health Inc, Janssen Biotech Inc, Merck, Pfizer Inc, Tolero Pharmaceuticals; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc.
  
  Celestia S Higano, MD
  Affiliate Professor, Department of Urologic Sciences
  University of British Columbia
  Director, Prostate Cancer Supportive Care Program
  Vancouver Prostate Centre
  Vancouver, British Columbia, Canada
  
  Consulting, Scientific Advisory Boards: Astellas, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Carrick Therapeutics, Clovis Oncology, Dendreon Pharmaceuticals Inc, Ferring Pharmaceuticals, Genentech, a member of the Roche Group, Hinova Pharmaceuticals Inc, Janssen Biotech Inc, Merck, Novartis, Orion Corporation, Pfizer Inc, Tolmar; Institutional Research Funding: Aptevo Therapeutics, Aragon Pharmaceuticals, Astellas, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Dendreon Pharmaceuticals Inc, eFFECTOR Therapeutics Inc, Emergent BioSolutions Inc, F Hoffman-La Roche Ltd, Ferring Pharmaceuticals, Genentech, a member of the Roche Group, Medivation Inc, a Pfizer Company, Pfizer Inc; Other: Spouse holds stock and former officer of CTI BioPharma Corp.
  
  David F Penson, MD, MPH, MMHC
  Hamilton and Howd Chair in Urologic Oncology
  Professor and Chairman, Department of Urology
  Nashville, Tennessee
  
  No financial interests or affiliations to disclose.
  
  Neal D Shore, MD
  Medical Director
  Carolina Urologic Research Center
  Atlantic Urology Clinics
  Myrtle Beach, South Carolina
  
  Advisory Committee and Consulting Agreements: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Clovis Oncology, Dendreon Pharmaceuticals Inc, FerGene, Ferring Pharmaceuticals, Foundation Medicine, Janssen Biotech Inc, MDxHealth, Merck, Myovant Sciences, Myriad Genetic Laboratories Inc, Nymox Pharmaceutical Corporation, Pfizer Inc, Sanofi Genzyme, Tolmar; Contracted Research: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Pfizer Inc, Sanofi Genzyme, Seagen Inc; Speakers Bureau: Astellas, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by an educational grant from Astellas and Pfizer Inc.
  
  Release date: October 2020
  Expiration date: October 2021